prikaz prve stranice dokumenta Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers
  Preuzmi
PDF 1.58 MB
Znanstveni rad - Pregledni rad
Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers
Frontiers in Immunology, 14 (2023); 1086006. https://doi.org/10.3389/fimmu.2023.1086006
Bojanić, Ines; Worel, Nina; Pacini, Carolina P.; Stary, Georg; Piekarska, Agnieszka; Flinn, Aisling M.; Schell, Kimberly J.; Gennery, Andrew R.; Knobler, Robert; Lacerda, João F.; Greinix, Hildegard T.; Pulanić, Dražen; Crossland, Rachel E.

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Bojanić, I., Worel, N., Pacini, C. P., Stary, G., Piekarska, A., Flinn, A. M. ... Crossland, R. E. (2023). Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers. Frontiers in Immunology, 14.. doi: 10.3389/fimmu.2023.1086006

Bojanić, Ines, et al. "Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers." Frontiers in Immunology, vol. 14, 2023. https://doi.org/10.3389/fimmu.2023.1086006

Bojanić, Ines, Nina Worel, Carolina P. Pacini, Georg Stary, Agnieszka Piekarska, Aisling M. Flinn, Kimberly J. Schell, et al. "Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers." Frontiers in Immunology 14 (2023). https://doi.org/10.3389/fimmu.2023.1086006

Bojanić, I., et al. (2023) 'Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers', Frontiers in Immunology, 14. doi: 10.3389/fimmu.2023.1086006

Bojanić I, Worel N, Pacini CP, Stary G, Piekarska A, Flinn AM, i sur.. Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers. Frontiers in Immunology [Internet]. 17.02.2023. [pristupljeno 23.11.2024.];14. doi: 10.3389/fimmu.2023.1086006

I. Bojanić, et al., "Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers", Frontiers in Immunology, vol. 14, Veljača 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:149689. [Citirano: 23.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:149689
Podaci o radu
Naslov (engleski)Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers
AutorInes Bojanić
AutorNina Worel
AutorCarolina P. Pacini
AutorGeorg Stary
AutorAgnieszka Piekarska
AutorAisling M. Flinn
AutorKimberly J. Schell
AutorAndrew R. Gennery
AutorRobert Knobler
AutorJoão F. Lacerda
AutorHildegard T. Greinix
AutorDražen Pulanić
AutorRachel E. Crossland
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Haematopoietic stem cell transplantation (HSCT) is the treatment of choice for malignant haematological diseases. Despite continuous improvements in pre- and post-transplantation procedures, the applicability of allo-HSCT is limited by life-threatening complications such as graft-versus-host disease (GvHD), engraftment failure, and opportunistic infections. Extracorporeal photopheresis (ECP) is used to treat steroid resistant GvHD with significant success. However, the molecular mechanisms driving its immunomodulatory action, whilst preserving immune function, require further understanding. As ECP is safe to administer with few significant adverse effects, it has the potential for earlier use in the post-HSCT treatment of GvHD. Thus, further understanding the immunomodulatory mechanisms of ECP action may justify more timely use in clinical practice, as well as identify biomarkers for using ECP as first line or pre-emptive GvHD therapy. This review aims to discuss technical aspects and response to ECP, review ECP as an immunomodulatory treatment modality for chronic GvHD including the effect on regulatory T cells and circulating vs. tissue-resident immune cells and consider the importance of emerging biomarkers for ECP response.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaFrontiers in Immunology
Brojčani podacivol. 14, 1086006
e-ISSN1664-3224
DOIhttps://doi.org/10.3389/fimmu.2023.1086006
URN:NBNurn:nbn:hr:105:149689
Datum objave publikacije2023-02-17
URL dokumentahttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1086006/full
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-01-15 07:54:25